Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients

Publisher： Karger

E-ISSN： 1421-9794|48|5|252-258

ISSN： 0009-3157

Source： Chemotherapy, Vol.48, Iss.5, 2002-12, pp. : 252-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

By Baer William H. Maini Archana Jacobs Ira

Pharmaceuticals, Vol. 7, Iss. 5, 2014-05 ,pp. : 530-544

MDPI

Access to resources Recommend Favorite

Parity, Age at First Birth, and Risk of Death from Non-Hodgkin’s Lymphoma: A Population-Based Cohort Study in Taiwan

By Chen Brian K. Yang Chun-Yuh

International Journal of Environmental Research and Public Health, Vol. 12, Iss. 8, 2015-08 ,pp. : 9131-9140

MDPI

Access to resources Recommend Favorite

Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 122-126

Karger

Access to resources Recommend Favorite

Campylobacter jejuni Fatal Sepsis in a Patient with Non-Hodgkin’s Lymphoma: Case Report and Literature Review of a Difficult Diagnosis

By Gallo Maria Teresa Di Domenico Enea Gino Toma Luigi Marchesi Francesco Pelagalli Lorella Manghisi Nicola Ascenzioni Fiorentina Prignano Grazia Mengarelli Andrea Ensoli Fabrizio

International Journal of Molecular Sciences, Vol. 17, Iss. 4, 2016-04 ,pp. : 544-544

MDPI

Access to resources Recommend Favorite

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma

By Knecht Hans Righolt Christiaan Mai Sabine

Cancers, Vol. 5, Iss. 2, 2013-06 ,pp. : 714-725

MDPI

Access to resources Recommend Favorite